ASX:MSBBiotechs
Is Mesoblast (ASX:MSB) Cheap Following Its Stronger Full Year Earnings?
What Mesoblast’s latest earnings tell you about the business
Mesoblast (ASX:MSB) has attracted fresh attention after reporting full year 2026 results on 26 August, with revenue of US$120.25 million and a reduced net loss of US$57.5 million compared with the prior year.
For investors watching Mesoblast stock, the combination of higher reported revenue and a smaller loss per share, both basic and diluted, puts the company’s regenerative medicine pipeline and funding needs back in...